Theraclone Sciences

Theraclone Sciences, based in Seattle, is a biotech company founded with the mission to develop innovative therapeutic antibodies aimed at treating infectious diseases and inflammation. The company's core vision revolves around leveraging advanced screening technology to identify rare, highly effective human monoclonal antibodies. Theraclone’s primary focus is on creating safe and effective therapeutic products, with a notable emphasis on infectious diseases such as HIV.

Notable affiliated people include key scientists and researchers who have contributed significantly to the field of antibody therapy. Theraclone has achieved significant milestones, including the licensing of their HIV broadly neutralizing fully-human antibodies to Gilead Sciences for further development. This partnership underscores the company's impact on advancing treatments for infectious diseases, positioning Theraclone Sciences as a pivotal player in the biotech industry.